Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.27), $0.17 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $110 million versus the consensus estimate of $103.34 million.

At June 30, 2020, ACADIA’s cash, cash equivalents, and investment securities totaled $658.6 million, compared to $697.4 million at December 31, 2019.

GUIDANCE:

• NUPLAZID net sales guidance is updated to $430 to $450 million from the previous range of $420 to $450 million.
• GAAP R&D guidance is decreased to $265 to $280 million from the previous range of $270 to $285 million.
• GAAP SG&A guidance is decreased to $400 to $420 million from the previous range of $425 to $445 million.
• Non-cash stock-based compensation expense guidance of $90 to $100 million is unchanged compared to prior guidance.
• 2020 year-end cash, cash equivalents, and investment securities is expected to be $570 to $590 million from a previous range of $470 to $500 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.